The correlates of novel cardiovascular predictive biomarker: Hyperhomocysteinemia
Hyperhomocysteinemia is characterized by an abnormally high level of Homocysteine and is seen in about 5% to 12% of the general population. In alcoholics and chronic kidney disease patients, this condition is more common.
Elevated Homocysteine irritates the lining of the blood vessels and increased the risk of thrombus formation, by causing them to become scarred, hardened, and furry. After adjusting for conventional risk factors, Homocystein level besides three other novel biomarkers, most strongly predicted the risk of death in an analysis from the Framingham Heart Study.
Purpose: The aim of the study was to delineate the factors associated with hyperhomocysteinemia in adult population.
Methods: Four hundred patients seeking health care in a medical clinic were included in the study. For each patient, socio-demographic, laboratory and clinical information about co-morbid conditions (OSA, hypertension and diabetes, cardiac diseases) were obtained. Logistic models with forward selection methods were employed and the outcome variable was homocysteine >12 μmol/L.
Sixty six patients (16.5%) with hyperhomocysteinemia were mostly older, females, nonsmoker, and obese. However, multivariate analysis indicated that high factorVIII (OR 2.59, P=0.001), D-dimer (OR 1.69, P=0.007), impaired diffusing capacity of the lung for carbon monoxide DLC0, (OR 2.04, P=0.017), were the only determinants of hyperhomocysteinemia after controlling for demographic and comorbid condition.
High factorVIII, high D-dimer’s association with hyperhomocysteinemia raises the query that may be these thrombotic risk factors increase the risk of thrombosis through hyperhomocysteinemia. Identification of novel biomarkers for prediction of thromboembolic events will be the hallmark of risk identification, early detection and prevention.